CYTK
NASDAQCytokinetics Incorporated
Price$77.44-0.87 (-1.10%)
01:30 PM07:45 PM
News · 26 weeks121-44%
2026-03-012026-08-23
Mix5290d
- Insider34(65%)
- Other10(19%)
- SEC Filings5(10%)
- Analyst1(2%)
- Earnings1(2%)
- Offering1(2%)
Latest news
25 items- PRCytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy Company to Host In-Person and Virtual Investor Event to Discuss Results fromLate-Breaking Science Presentations SOUTH SAN FRANCISCO, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced upcoming presentations, including a Hot Line presentation and two Late Breaking Science presentations, at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany. Hot Line and Late-Breaking Science Presentations Title: ACACIA-HCM: Aficamten for Symptomatic Nonob
- INSIDEREVP Research & Development Malik Fady Ibraham exercised 3,500 shares at a strike of $7.80 and sold $265,370 worth of shares (3,500 units at $75.82) (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- PRCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on August 14, 2026 it granted stock options to purchase an aggregate of 27,565 shares of common stock and 18,273 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 12 employees, whose employment commenced in July and August 2026 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of th
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cytokinetics IncorporatedSCHEDULE 13G/A - CYTOKINETICS INC (0001061983) (Subject)
- SECCytokinetics Incorporated filed SEC Form 8-K: Other Events8-K - CYTOKINETICS INC (0001061983) (Filer)
- INSIDERPresident & CEO Blum Robert I exercised 7,500 shares at a strike of $10.60 and sold $575,700 worth of shares (7,500 units at $76.76) (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- SECSEC Form 10-Q filed by Cytokinetics Incorporated10-Q - CYTOKINETICS INC (0001061983) (Filer)
- SECCytokinetics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CYTOKINETICS INC (0001061983) (Filer)
- PRCytokinetics Reports Second Quarter 2026 Financial Results and Provides Business UpdateMYQORZO® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 MYQORZO Launched in Germany, Approved in United Kingdom and Regulatory Review Ongoing in Canada, Switzerland, Hong Kong and Taiwan ~$1.7 Billion in Cash, Cash Equivalents and Investments as of June 30, 2026 SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the second quarter of 2026. "Our second quarter results demonstrate commercial launch momentum for MYQORZO alongsid
- INSIDEREVP, Chief Commercial Officer Callos Andrew exercised 14,000 shares at a strike of $23.26 and sold $1,118,320 worth of shares (14,000 units at $79.88) (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- PRCytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and WalesAuthorisation from MRHA and Recommendation from NICE This announcement is intended for business and financial media and investors only SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted MYQORZO® (aficamten) a marketing authorisation across the United Kingdom for the treatment of symptomatic (New York Heart Association, NYHA class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in eligible adult patients. At the same time the National Institute for Health and Care Excellence (NICE) has issued guidance recommending aficamten for use in
- INSIDERPresident & CEO Blum Robert I exercised 7,500 shares at a strike of $10.60 and sold $606,525 worth of shares (7,500 units at $80.87) (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDEREVP Research & Development Malik Fady Ibraham exercised 3,500 shares at a strike of $7.80 and sold $282,065 worth of shares (3,500 units at $80.59) (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- PRCytokinetics to Announce Second Quarter Results on August 6, 2026SOUTH SAN FRANCISCO, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report second quarter results on August 6, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com or directly at the following link: Cytokinetics Q2 2026 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics’ w
- PRCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on July 15, 2026 it granted stock options to purchase an aggregate of 21,220 shares of common stock and 14,067 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 10 employees, whose employment commenced in June and July 2026 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the gr
- INSIDERDirector Wysenski Nancy was granted 75 shares, increasing direct ownership by 0.22% to 33,992 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Wierenga Wendell was granted 75 shares, increasing direct ownership by 0.21% to 35,563 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Kaye Edward M. Md was granted 151 shares, increasing direct ownership by 1% to 10,434 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Henderson John T was granted 272 shares, increasing direct ownership by 0.35% to 78,360 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Harrington Robert Arthur was granted 151 shares, increasing direct ownership by 0.69% to 21,932 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERDirector Daly James M was granted 151 shares, increasing direct ownership by 5% to 3,390 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- INSIDERPresident & CEO Blum Robert I sold $615,150 worth of shares (7,500 units at $82.02) and exercised 7,490 shares at a strike of $10.60, decreasing direct ownership by 0.00% to 377,820 units (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cytokinetics IncorporatedSCHEDULE 13G/A - CYTOKINETICS INC (0001061983) (Subject)
- INSIDEREVP Research & Development Malik Fady Ibraham exercised 3,500 shares at a strike of $7.80 and sold $303,170 worth of shares (3,500 units at $86.62) (SEC Form 4)4 - CYTOKINETICS INC (0001061983) (Issuer)
- PRCytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy Company to Host In-Person and Virtual Investor Event to Discuss Results from Late-Breaking Science Presentations SOUTH SAN FRANCISCO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced three Late Breaking Science abstracts were accepted for presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany, including a Hot Line presentation of the primary results from ACACIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients
CYTK FAQ
7 questionsWhat does Cytokinetics Incorporated do?
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat...Where does CYTK stock trade?
Cytokinetics Incorporated (CYTK) is listed on NASDAQ.What sector and industry is CYTK in?
Cytokinetics Incorporated operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Cytokinetics Incorporated go public?
Cytokinetics Incorporated (CYTK) completed its IPO in 2004.What are analysts saying about CYTK?
Cytokinetics Incorporated has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-06-29.What companies are similar to CYTK?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CYTK side-by-side with any of them on Quantisnow.How can I track CYTK on Quantisnow?
Quantisnow aggregates Cytokinetics Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CYTK to receive live email and push alerts on every new disclosure.